Unity Biotechnology, Inc. (0YC0.L)

USD 1.02

(-1.45%)

Market Cap (In USD)

17.18 Million

Revenue (In USD)

-

Net Income (In USD)

-39.86 Million

Avg. Volume

551.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.02-3.788
PE
-
EPS
-
Beta Value
0.827
ISIN
US91381U2006
CUSIP
91381U200
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Dr. Anirvan Ghosh Ph.D.
Employee Count
-
Website
https://unitybiotechnology.com
Ipo Date
2018-10-04
Details
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.